Psychometric properties of the French Female Sexual Function Index (FSFI)

Wylomanski, S.; Bouquin, R.; Philippe, Henri-Jean; Poulin, Yves; Hanf, Matthieu; Dréno, Brigitte; Rouzier, Roman; Quéreux, G.

doi:10.1007/s11136-014-0652-5

Cited by 54 publications

(37 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding indicates the ability of FSFI to capture variation in our data and is consistent with the study by Wylomanski et al (2014) who did not find a floor effect in a study of French women seeking gynaecology consultation, although two items (items 9 and 10) had a ceiling effect. It appears that data variability was evident in our study; however, the issue of possible ceiling effects of the FSFI is worth further investigation.…”

Section: Discussionsupporting

confidence: 92%

“…Of these, the Female Sexual Function Index (FSFI) is widely used in research (Rosen, 2002;DeRogatis, 2008) and has been translated into many different languages (Berne et al, 2004;Rellini et al, 2005;Pechorro et al, 2012;Wylomanski et al, 2014). The FSFI was originally developed in the USA to assess six domains of FSD, including desire, arousal, lubrication, orgasm, satisfaction, and pain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sexual function in cervical cancer patients: Psychometric properties and performance of a Chinese version of the Female Sexual Function Index

Liu

Chen

et al. 2016

European Journal of Oncology Nursing

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Sexual function in cervical cancer patients: Psychometric properties and performance of a Chinese version of the Female Sexual Function Index

Liu

Chen

et al. 2016

European Journal of Oncology Nursing

View full text Add to dashboard Cite

“…The total score ranges between 2 and 36; higher scores are associated with a lower degree of female sexual dysfunction (FSD). A consensus seems to be found in the literature for values of less than 23 to de ne FSD [37,39]. A good reliability has been described for the French version with intraclass correlation coe cients superior to 0.75 and Cronbach's coe cients superior to 0.8 similarly to the original English version.…”

Section: Sexual Functionmentioning

confidence: 95%

“…The impact of perineal pain on female sexuality will be assessed by the French validated version of the FSFI [37,38] using an online questionnaire at D7, M3 and M6. This 19-items questionnaire is adapted for both sexually active and non-active women, and allows the assessment of the different parts of sexual function (desire, arousal, lubrication, orgasm, satisfaction and pain) over the past four weeks.…”

Section: Sexual Functionmentioning

confidence: 99%

See 1 more Smart Citation

Ropivacaine 75mg versus placebo in perineal infiltration for analgesic efficacy at mid- and long-term for episiotomy repair in postpartum women- The ROPISIO study: a two-center, randomized, double-blind, placebo-controlled trial.

Cardaillac

Ploteau

Thuaut

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Perineal pain due to episiotomy is commonly reported and can be severe enough to disturb the mother-infant dyad during the postpartum period. Its incidence at day 7 postpartum varies from 63% to 74%. Recent studies have already investigated the analgesic efficacy of perineal infiltration of ropivacaine after episiotomy, but have only focused on the immediate postpartum period (at 24 and 48 hours after birth). Large, adequately powered, multicenter, randomized controlled trials are required to evaluate the impact of ropivacaine infiltration on perineal pain and mid- and long-term quality of life before the widespread use of ropivacaine to prevent perineal pain after episiotomy can be recommended. Methods The ROPISIO study is a two-center, randomized, double-blind, placebo-controlled trial in La Roche sur Yon and Nantes, France. It will involve 272 women with vaginal singleton delivery and mediolateral episiotomy at term (≥ 37 weeks). Perineal infiltration (ropivacaine 75mg or placebo) will be administrated just after vaginal birth and before episiotomy repair. The primary outcome will be the analgesic efficacy at day 7 postpartum (mid-term), defined by the numerical rating scale of pain (ENS NRS) strictly superior to 3/10 on the perineal repair area. Secondary outcomes will be the analgesic efficacy (ENS NRS), the impact of pain on daily behavior, on the quality of life (36-Item Short Form Health Survey), on the occurrence of symptoms of postpartum depression (Edinburgh Postnatal Depression Scale) and on sexuality (Female Sexual Function Index) at 3 and 6 months (long-term) using validated online questionnaires. This study will have 90% power to show approximately 30% relative risk reduction in the incidence of perineal pain at day 7, from 70.0% to 50.0%. Discussion Ropivacaine is a promising candidate drug, inexpensive, easy to administer, and would be suitable to include in the routine management of deliveries in labor ward. This study will investigate if perineal ropivacaine infiltration just after birth can reduce mid- and long-term postpartum pain and increase quality of life in women with mediolateral episiotomy.

show abstract

A psychometric evaluation of the Female Sexual Function Index in women treated for breast cancer

et al. 2022

View full text Add to dashboard Cite

Background:We aimed to determine the psychometric properties and factor structure of the 19-item Female Sexual Function Index (FSFI) in 132 sexually active women previously treated for breast cancer.Methods: Confirmatory factor analysis explored three models: (a) second-order six-factor, (b) six-factor, and (c) five-factor models combining the desire and arousal subscales.Results: Results revealed excellent reliability for the total score (Cronbach's α = 0.94), and domain scores (all Cronbach's αs > 0.90), and good convergent and discriminant validity. The six-factor model provided the best fit of the models assessed, but a marginal overall fit (Tucker-Lewis index = 0.91, comparative fit index = 0.93, root mean square error of approximation = 0.09). Exploratory factor analyses (EFA) supported a four-factor structure, revealing an arousal/orgasm factor alongside the original pain, lubrication, and satisfaction domains. Conclusion:The arousal/orgasm factor suggests a "sexual response" construct, potentially arising from an underlying latent factor involving physical and mental stimulation in conceptualizations of arousal and orgasm in women treated for breast cancer. Finally, the EFA failed to capture an underlying desire factor, potentially due to measurement error associated with the small number of items (two) in this domain. Despite evidence that the FSFI has sound psychometric properties, our results suggest that the current conceptualizations of the FSFI might not accurately represent sexual functioning in women previously treated for breast cancer. Further research is required to elucidate the factors that influence desire, arousal, and orgasm in sexually active women in this population, and the reasons underlying sexual inactivity. Practical and theoretical implications for FSFI use in this population are discussed.

show abstract

Psychometric properties of the French Female Sexual Function Index (FSFI)

Abstract: Our study demonstrated similar or adequate psychometric properties of the French version of the FSFI compared to the original English version.

Cited by 54 publications

References 15 publications

Sexual function in cervical cancer patients: Psychometric properties and performance of a Chinese version of the Female Sexual Function Index

Sexual function in cervical cancer patients: Psychometric properties and performance of a Chinese version of the Female Sexual Function Index

Ropivacaine 75mg versus placebo in perineal infiltration for analgesic efficacy at mid- and long-term for episiotomy repair in postpartum women- The ROPISIO study: a two-center, randomized, double-blind, placebo-controlled trial.

A psychometric evaluation of the Female Sexual Function Index in women treated for breast cancer

Contact Info

Product

Resources

About